Pulse Biosciences, Inc., known for its innovative nPulse technology using Nanosecond Pulsed Field Ablation energy, announced that its Board of Directors’ Compensation Committee has approved equity inducement awards for two newly hired employees.
Health Technology Insights: Allink Biotherapeutics Secures $47Million Series A Extension
These awards were granted outside the 2017 Equity Incentive Plan but under the terms of the 2017 Inducement Equity Incentive Plan and were issued on December 15, 2025, in compliance with Nasdaq Listing Rule 5635(c)(4).
The awards allow the recipients to purchase up to a combined total of 3,400 shares of Pulse common stock at an exercise price of $14.13 per share, which reflects the closing price of the stock on the grant date.
Health Technology Insights: Cosette Pharma Launches First Generic CIPRO HC with CGT Exclusivity
The stock options will vest over a four-year period with one quarter vesting each year, contingent upon continued employment.
The awards are governed by the terms of the 2017 Inducement Equity Incentive Plan and the individual award agreements with each employee, and the Compensation Committee views them as a key part of attracting and retaining talent essential to advancing Pulse Biosciences’ mission.
Health Technology Insights: Victor Miller Joins NorthStar Medical Radioisotopes, LLC as Chief Financial Officer
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
